EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type

Takaaki Konuma iD, Kazuaki Kameda, Kaoru Morita iD, Tadakazu Kondo iD, Fumihiko Kimura iD, Hideki Nakasone iD, Fumihiko Ouchi, Naoyuki Uchida iD, Masatsugu Tanaka, Tetsuya Nishida, Takahiro Fukuda, Yuta Hasegawa und 13 weitere

American Journal of Hematology · 2025-01 · 100 (1) · 66-77

DOI: 10.1002/ajh.27521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 20.11.2024. Verfasst von Takaaki Konuma und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Granulocyte Colony-Stimulating Factor, Graft vs Host Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, AMED, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We retrospectively evaluated the impacts of using granulocyte colony‐stimulating factor (G‐CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single‐unit cord blood transplantation (CBT). Multivariate analysis showed that G‐CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT. However, it was associated with a higher risk of grades II–IV acute graft‐versus‐host disease (GVHD) across all graft types. Moreover, an increased incidence of overall chronic GVHD was observed with G‐CSF administration in BMT and CBT patients, but not in PBSCT patients. G‐CSF administration significantly improved overall survival (OS) and leukemia‐free survival (LFS) only following CBT. Regarding the timing of G‐CSF, in comparison with late initiation of G‐CSF (Days 5–10), early initiation (Days 0–4) did not provide benefits for hematopoietic recovery regardless of graft type. In contrast, late initiation was significantly associated with a lower risk of grades II–IV acute GVHD and better OS and LFS in CBT patients. These data demonstrated that G‐CSF administration accelerated neutrophil recovery and increased the risk of grades II–IV acute GVHD across all graft types, but significantly improved survival outcomes but only following CBT. Therefore, routine use of G‐CSF should be considered for CBT in adult patients with AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteGranulocyte Colony-Stimulating FactorGraft vs Host DiseaseHumansAdultMaleMiddle AgedFemaleRetrospective StudiesAgedHematopoietic Stem Cell TransplantationAdolescentPeripheral Blood Stem Cell TransplantationYoung AdultCord Blood Stem Cell TransplantationBone Marrow TransplantationTreatment OutcomeTransplantation, Homologous

Substanzen

Granulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
  • Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan.

ORCID-Profile: Takaaki Konuma, Kaoru Morita, Tadakazu Kondo, Fumihiko Kimura, Hideki Nakasone, Naoyuki Uchida, Shuichi Ota, Noboru Asada, Makoto Yoshimitsu, Yoshinobu Kanda, Masamitsu Yanada

Förderung

  • Japan Agency for Medical Research and Development, AMED
  • Japan Agency for Medical Research and Development

Zitieren

APA

Konuma, T., Kameda, K., Morita, K., Kondo, T., Kimura, F., Nakasone, H., Ouchi, F., Uchida, N., Tanaka, M., Nishida, T., Fukuda, T., Hasegawa, Y., Sakata-Yanagimoto, M., Onizuka, M., Sawa, M., Ota, S., Asada, N., Fujiwara, S. I., Yoshihara, S., …, & Yanada, M. (2025). Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. American Journal of Hematology, 100(1), 66-77. https://doi.org/10.1002/ajh.27521

Vancouver

Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, et al. Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. American Journal of Hematology. 2025;100(1):66-77. doi:10.1002/ajh.27521

BibTeX
@article{Konuma2025,
  author = {Konuma, Takaaki and Kameda, Kazuaki and Morita, Kaoru and Kondo, Tadakazu and Kimura, Fumihiko and Nakasone, Hideki and Ouchi, Fumihiko and Uchida, Naoyuki and Tanaka, Masatsugu and Nishida, Tetsuya and Fukuda, Takahiro and Hasegawa, Yuta and Sakata-Yanagimoto, Mamiko and Onizuka, Makoto and Sawa, Masashi and Ota, Shuichi and Asada, Noboru and Fujiwara, Shin-Ichiro and Yoshihara, Satoshi and Ishimaru, Fumihiko and Yoshimitsu, Makoto and Kanda, Yoshinobu and Ohbiki, Marie and Atsuta, Yoshiko and Yanada, Masamitsu},
  title = {Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {1},
  pages = {66--77},
  doi = {10.1002/ajh.27521}
}
Kostenlos starten →